Description:
Metametrix Estronex 2/16 OH Estrogen Ratio helps women to determine their risk for breast cancer. The Estronex 2/16 Test from Metametrix Clinical Laboratory measures the ratio of these two critical estrogen metabolites from a single urine specimen. Estronex 2/16 ratios less than 2.0 indicate increasing long-term risk for breast, cervical, and other estrogen-sensitive cancers. Importantly, nutritional interventions can help raise Estronex 2/16 ratios and decrease long-term risk. The Estronex 2/16 Test features: A simple first-morning urine specimen; no blood draw is necessary. Economical, so you can retest often to monitor therapy. Bone Resorption Test can be added for osteoporosis risk assessment at only a small incremental cost. Doctors order provided, you receive the results.

To See A Sample Report Click Here!

When a major study of hormone replacement therapy in women was recently discontinued, clinicians and patients alike were left with unanswered questions. Why are certain tissues, such as the breast, susceptible to estrogen-induced cancer? Why are some women susceptible, but not others? Researchers at Rockefeller University have found that the body metabolizes estrogens into several different metabolites that can impact cancer development.